Bone-Directed Drug Delivery: From Mineral and Matrix Recognition to Cellular Regulation
- 1Laboratory of Bone Metabolism and Control, Department of Microbiology, Yeungnam University College of Medicine, Daegu 42415, Republic of Korea
Abstract
Bone-targeted drug delivery aims to increase drug exposure at diseased skeletal sites while reducing unnecessary exposure in non-skeletal tissues. Bone provides two complementary targets—the mineralized extracellular matrix and the cells regulating bone remodeling. Structural targeting uses the calcium- and phosphate-rich hydroxyapatite surfaces or collagen-rich extracellular matrix as binding sites for therapeutic cargos and delivery carriers. Cellular targeting aims to regulate osteoclasts, osteoblast-lineage cells, osteocytes, and key remodeling pathways, including receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin, Wnt/sclerostin, bone morphogenetic protein, and parathyroid hormone 1 receptor signaling. Targeting ligands and delivery platforms, including bisphosphonates, acidic oligopeptides, tetracyclines, collagen-hybridizing peptides, calcium phosphate materials, nanoparticles, aptamers, nucleic acid vectors, and extracellular vesicles, have been developed to enhance skeletal localization, prolong retention, improve cellular uptake, and control cargo release. Clinical experience with anti-RANKL antibodies, sclerostin antibodies, and parathyroid hormone receptor agonists further demonstrates the therapeutic value of regulating bone-remodeling pathways. Successful translation requires more than skeletal accumulation and should establish microanatomical localization, target-cell engagement, cargo release, therapeutic efficacy, and long-term safety. Integrating structural and cellular targeting may enable more precise treatment of osteoporosis, fracture repair, bone infection, and skeletal malignancies.
Related
- Antibiotic and growth factor-loaded hydrogels for infected bone defect repair: mechanisms of spatiotemporal delivery and cellular microenvironment regulation.
- PDGFRα-directed fibroblast-homing peptides for targeted delivery of nucleic acid therapeutics
- Hepa-SENS: ASGPR-mediated hepatocyte delivery and attenuated unwanted immune recognition for nucleic acid therapeutics
- Glycosaminoglycan Recognition by YKL-40: Potential Regulation in Disease
- Bioactive small-molecule gas delivery for enhanced bone regeneration: modulation of cellular signaling and remodeling of the regenerative microenvironment.
BibTeX
@article{kim2026bonedirected,
title = {{Bone-Directed Drug Delivery: From Mineral and Matrix Recognition to Cellular Regulation}},
author = {Raeyeong Kim and Daewon Jeong},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = nov,
doi = {10.3390/ijms272210062},
url = {https://www.mdpi.com/1422-0067/27/22/10062},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Bone-Directed Drug Delivery: From Mineral and Matrix Recognition to Cellular Regulation
AU - Raeyeong Kim
AU - Daewon Jeong
PY - 2026
DA - 2026/11/10
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms272210062
UR - https://www.mdpi.com/1422-0067/27/22/10062
AB - Bone-targeted drug delivery aims to increase drug exposure at diseased skeletal sites while reducing unnecessary exposure in non-skeletal tissues. Bone provides two complementary targets—the mineralized extracellular matrix and the cells regulating bone remodeling. Structural targeting uses the calcium- and phosphate-rich hydroxyapatite surfaces or collagen-rich extracellular matrix as binding sites for therapeutic cargos and delivery carriers. Cellular targeting aims to regulate osteoclasts, osteoblast-lineage cells, osteocytes, and key remodeling pathways, including receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin, Wnt/sclerostin, bone morphogenetic protein, and parathyroid hormone 1 receptor signaling. Targeting ligands and delivery platforms, including bisphosphonates, acidic oligopeptides, tetracyclines, collagen-hybridizing peptides, calcium phosphate materials, nanoparticles, aptamers, nucleic acid vectors, and extracellular vesicles, have been developed to enhance skeletal localization, prolong retention, improve cellular uptake, and control cargo release. Clinical experience with anti-RANKL antibodies, sclerostin antibodies, and parathyroid hormone receptor agonists further demonstrates the therapeutic value of regulating bone-remodeling pathways. Successful translation requires more than skeletal accumulation and should establish microanatomical localization, target-cell engagement, cargo release, therapeutic efficacy, and long-term safety. Integrating structural and cellular targeting may enable more precise treatment of osteoporosis, fracture repair, bone infection, and skeletal malignancies.
SN - 1422-0067
ER -